reported on May 7 that Shuangcheng Pharmaceutical (002693) showed abnormal movements today. As of press time, Shuangcheng Pharmaceutical was 6.5 yuan per share, an increase of 4.33%, a trading volume of 103,100 lots, a turnover rate of 2.55%, an amplitude of 6.74%, and a volume ratio of 1.48.
technical aspect, Shuangcheng Pharmaceutical (002693) is currently on the 30-day line, 5-day line, 10-day line, and 20-day line. The 5-day line of the stock is below the 10-day line, showing a " dead cross " state, and the short-term trend may be more pessimistic. The latest interim report of
shows that Shuangcheng Pharmaceutical (002693) achieved operating income of 95765554.61, net profit loss of 3444600, a year-on-year increase of 60.62%, and earnings per share -0.01. The pharmaceutical and biological industry where
Shuangcheng Pharmaceutical (002693) is located has an overall increase of 1.58%. The stocks in the sector, Longshenrongfa (300534), Sannuo Biotechnology (300298), and Xinguang Pharmaceutical (300519) rose significantly, up 10.01%, 10.0%, and 9.99% respectively; North China Pharmaceutical (600812), Zhengchuan Co., Ltd. (603976), and Modern Pharmaceutical (600420) significantly increased volume, with a volume ratio of 4.2, 3.83, and 3.6 respectively; related stocks with larger amplitudes include Xinguang Pharmaceutical (300519), Enhua Pharmaceutical (002262), and Sannuo Biotechnology (300298), with amplitudes of 14.39%, 9.83%, and 9.79% respectively;
Shuangcheng Pharmaceutical (002693) are mainly engaged in polypeptide products and other businesses.
Since its establishment, Hainan Shuangcheng Pharmaceutical Co., Ltd. has been engaged in the research, development, production and sales of chemical synthetic polypeptide drugs. It has become one of the key backbone enterprises in my country's chemical synthetic polypeptide industry. The company's leading product, Thymus For Injection (trade name "Jitai"), is the second domestic brand to be listed in China. It was recognized as a provincial high-tech project by the Hainan Provincial Department of Science and Technology in 2001 and was included in the National Torch Plan by the Ministry of Science and Technology in 2004. Thymus For Injection has entered the 2009 edition of the "Medical Insurance Catalog" and the 2010 edition of the "Chinese Pharmacopoeia", and was included in the tumor category by the 2010 edition of the "China National Prescription Collection". It is also the only non-specific immunomodulator recommended in the immunomodulatory treatment of "China Chronic Hepatitis B Prevention and Treatment Guidelines (2010)" and "Asia-Pacific Chronic Hepatitis B Management Consensus (2008)".
([Disclaimer] This article was published by Xiaomingbot, a headline writing robot. It is only for users to obtain information and does not constitute investment advice. You are responsible for your own profits and losses based on this. Investors must know that the market is risky and investment should be cautious.)
